Analyst
Citi
Equibles does not estimate personal net worth.
Samantha Semenkow is recorded as Analyst at Citi. Samantha Semenkow has spoken on 12 earnings calls and 4 other investor events across 10 companies, most recently for Nektar Therapeutics on October 1, 2026. Those appearances were for Nektar Therapeutics (NKTR), Agios Pharmaceuticals, Inc. (AGIO), Allogene Therapeutics, Inc. (ALLO), Argenx SE (ARGX), Wave Life Sciences, Inc. (WVE) and 5 other companies. The companies whose calls Samantha Semenkow spoke on are classified in the Healthcare sector.
“My question is just about the greater response durability you seem to see with the patients that were treated through week 52.”
“Thanks very much for taking the question, and thank you for all of the details in the recent market research that you shared in atopic derm. I'm just wondering if you can elaborate a bit more on how physicians are thinking about prescribing ResPeg in the first-line setting.”
“And, Zach, let me add my congratulations on your first call as CEO. So just another one on Alpha 3. We look forward to the interim EFS analysis mid-next year. Just wondering how we should think about that analysis in terms of the potential for overwhelming benefit to be demonstrated.”
“You outlined in your slides market expansion opportunity. Mindy, I'm wondering what you're seeing in the data about treatment-naive patients utilizing VivGuard as a first line.”
“I have two, one for the physicians on the call and one for management. For the physicians, you know, in the fireside chat portion, which is very helpful, you mentioned how important reduction and transfusion burden is.”
Citi
Analyst
Source not stated
NKTR
Biotechnology · Healthcare
ARGX
Biotechnology · Healthcare
BIOA
Drug Manufacturers - Specialty & Generic · Healthcare
IMVT
Biotechnology · Healthcare
